

ASTRIA CONNECTION: HAE

November 2023

New STAR-0215 Phase 1a Data

Earlier this month, Astria shared new data supporting the potential for **STAR-0215** to be dosed two or four times per year as a preventative therapy for HAE with robust attack suppression and low treatment burden.

Our Phase 1a trial of **STAR-0215** assessed safety and tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) in people without HAE. Interim results from the trial confirmed **STAR-0215**'s potential to prevent HAE attacks with dosing two or four times per year. **STAR-0215** was well-tolerated, exhibited low risk of injection pain, and we did not see any serious adverse events. We also saw that **STAR-0215** reached levels associated with prevention of HAE attacks, which we believe will prevent HAE attacks less than one day after dosing. Our vision is to give people living with HAE the freedom to choose which dosing frequency works best for their lives with a therapy that has a trusted modality and mechanism. We are thrilled that these results bring us one step closer to our goal of helping to normalize the lives of HAE community members.

Additionally, we announced that we now expect to share initial proof-of-concept trial results from our ALPHA-STAR trial in people living with HAE in the first quarter of 2024. We look forward to sharing more with you in the new year. If you are interested in learning more, check out our press release [here](#).

HAEi Regional Conference EMEA 2023

In September, HAEi held a conference in Munich, Germany for the HAE communities based in Europe, the Middle East, and Africa. Over 600 people gathered to share their personal experiences with HAE, the latest research, and opportunities to advocate and take action. We were delighted to catch up with members of the HAE community as well as meet many new friends. It was truly inspiring listening to, learning from, and speaking with so many people from diverse backgrounds—all unified by a passion for improving the lives of HAE community members.

At the poster session, we were pleased to share research on patient preferences for efficacy measures when starting on or switching to a new preventative therapy for HAE. You can view our poster, "People Living with Hereditary Angioedema (HAE) Prioritize Attack-Free Status as a Target for Therapeutic Efficacy," [here](#).

Thank you to all who attended the conference and engaged with us at our booth and poster presentation! We continue to be immensely grateful for the opportunity to learn from the HAE community.

Check out some photos from the event on the right:



Hill Day 2023

In October, members of Astria's team traveled to Washington, D.C. to meet with key staff of lawmakers focused on critical healthcare policy to help amplify and advocate for the voices of people living with HAE. Our main priority is ensuring access to medicines.

If you are interested in learning more or getting involved in advocacy, click [here](#) to learn more about HAEA's Grassroots Advocacy network.



Upcoming Events from HAEA/HAEi:

Click the date to learn more:

[December 2, 2023:](#)

HAEA Boston Area
In-Person Meet and
Greet Lunch Event

[December 16, 2023:](#)

HAEA Hershey, PA
In-Person Meet and
Greet Lunch Event

[March 15-17, 2024:](#)

2024 HAEi Regional
Conference Americas in
Panama City, Panama

[May 16, 2024:](#)

hae day :) 2024

[October 3-6, 2024:](#)

2024 HAEi Global
Leadership Workshop in
Copenhagen, Denmark

ALPHA-STAR Trial

The ALPHA-STAR trial is a proof-of-concept Phase 1b/2 trial evaluating single and multiple doses of [STAR-0215](#) in people living with HAE types I and II. It is evaluating safety and tolerability, HAE attack rate, PK, PD, and quality of life in the enrolled participants.

Learn more about the ALPHA-STAR trial and our trial sites by visiting:

<https://astriatx.com/for-patients/alpha-star-trial/>.

Want the latest Astria Connection: HAE sent straight to your inbox?

Click [here](#) to subscribe.

For advocacy questions: advocacy@astriatx.com

Follow us on social media: [@AstriaTx](#)

